The medication is considered relevant across therapeutic domains involving upper and lower respiratory tract infections, particularly when caused by susceptible bacteria. This agent is primarily relevant across therapeutic domains where additional symptomatic support is needed against susceptible Gram-positive bacteria.

What Clofoctol Treats: Main Uses and Benefits

Clofoctol is relevant for easing symptoms related to systemic or localized discomfort associated with conditions involving acute bacterial manifestations of the ear, nose, and throat (ENT) and the respiratory system. It is commonly used to help with conditions presenting with infectious symptoms in the upper and lower respiratory tract, including tonsillitis and middle ear infections, especially when caused by susceptible Gram-positive organisms.

“The medication is applied in contexts where temporary physiological imbalance is a factor and is relevant when supportive symptom management is appropriate.”

It is also applied in clinical settings that involve acute or unstable symptom patterns. Clofoctol may be part of symptomatic management applied in scenarios where additional management of discomfort is required, such as following surgical procedures in the ENT region. The support provided contributes to improved comfort during periods of heightened symptoms, assisting with maintaining functional stability.

---

Quick Fact: Relevance for Symptom Management Clofoctol is commonly used to help manage symptom clusters that may become intense or disruptive in both pediatric and adult patient groups during acute episodes of bacterial respiratory or ENT infection.

Who can and cannot use Clofoctol?

The eligibility to use Clofoctol is officially defined by regulatory authorities based on a patient's constitutional factors and specific clinical status.

Official Eligibility Statements

Category	Regulatory Status
Populations for whom use is allowed	Use is established for Adults, Children, and Infants (Lattanti).
Populations for whom use is contraindicated	Patients with known Hypersensitivity to the active substance or its excipients; Patients with Active Diarrhea (Diarrea in atto).
Pregnancy and lactation eligibility	Conditional Use: Must be used only if absolutely necessary and under the control of a physician.

Eligibility Context

The regulatory profile prohibits use for individuals with a history of hypersensitivity to the drug or its components. The medicine is also contraindicated in the presence of active diarrhea. Use is established across all major age demographics, including infants and children. For pregnant and breastfeeding women, the official label restricts use to strictly necessary cases managed under mandatory medical supervision.

Clofoctol Interactions with other medicines and products

Official regulatory documentation, including prescribing information from major national health authorities, does not explicitly list specific drug-drug, pharmacokinetic, or pharmacodynamic interaction statements for Clofoctol that necessitate formal restrictions.

The official profile is defined by the absence of explicit regulatory caveats in the standard interaction domains, meaning no mandatory prohibitions or timing rules are specified.

---

Interaction Scope and Restrictions

Category	Official Regulatory Status
Medicinal product categories with documented interactions:	None explicitly listed. No specific drug classes are formally named as interacting partners.
Mechanistic basis of interactions (CYP, Transporters):	None explicitly documented. No official statement regarding metabolic enzyme (CYP) effects or drug transporter influences.
Timing-based interaction rules:	None explicitly documented. No mandatory separation of administration times is required for co-administered substances.
Food, Alcohol, Herbal Product Interactions:	None explicitly documented. No formal warnings or restrictions are specified for non-medicinal substances.
Contraindicated Combinations:	None explicitly documented based on an interaction mechanism within the official prescribing information.

---

Interaction Classifications (High-Level)

Category	Official Regulatory Status
Interaction severity classification:	No classification provided. The lack of documented interactions prevents formal classification (e.g., contraindicated, major, moderate).
Population-specific interaction notes:	None explicitly documented within the interaction sections for specific populations (e.g., pediatric, hepatic impairment).

Connection to the overall interaction profile: The regulatory profile for Clofoctol is notable for the absence of explicit, required restrictions across all standard interaction domains. There are no formal regulatory mandates for avoiding specific co-administered substances, managing enzyme-mediated risks, or separating administration times based on publicly accessible regulatory documentation.

Clofoctol's mechanism of action involves two distinct domains: targeting bacterial translation and modulating host cell processes. Its primary action is inhibition through direct binding to the 50S ribosomal subunit of susceptible bacteria. This interaction obstructs the peptidyl transferase center, preventing the formation of peptide bonds and halting the elongation phase of the nascent polypeptide chain. The resulting cessation of protein synthesis disrupts essential cellular processes in the pathogen.

Separately, in eukaryotic cells, clofoctol functions as an activator of stress signaling. It induces endoplasmic reticulum (ER) stress, which leads to the activation of the Unfolded Protein Response (UPR) pathways. Activation of the PERK-eIF2alpha axis, a key UPR sensor, results in the selective suppression of global protein translation within the host cell. The compound also interacts with key regulatory proteins, including the Cdc7/Dbf4 protein kinase complex and the mRNA-binding protein CSDE1, modifying early molecular steps in pathways related to gene expression and cell cycle regulation.

The administration of Clofoctol is structured around specific requirements for route, frequency, and dosage strength to ensure proper systemic delivery. The compound is officially classified as an antibacterial agent intended for systemic use.

---

Administration Route and Dosing

The officially approved method for systemic delivery of Clofoctol is the rectal route using the suppository dosage form. This administration method defines the overall usage protocol, as it renders common oral timing instructions, such as those related to meals, irrelevant. The standard adult dosing regimen specifies 750 mg per single dose, which corresponds to a 1500 mg total daily dose when administered according to the labeled frequency.

---

Frequency and Duration

Clofoctol is typically administered twice daily (BID), which establishes a necessary 12-hour interval between doses. This schedule is designed to maintain the required systemic presence of the medication. The general context specifies that the drug is for short-term use only, consistent with acute treatment protocols, and is not authorized for long-term or indefinite maintenance regimens.

---

Population-Specific Rules

Specific dosage strengths are officially recognized for different patient groups. Lower strength suppositories, including 100 mg and 200 mg, are available and designated for use in the pediatric population. The administration of these strengths is governed by detailed, weight- or age-based guidelines specified in the official labeling.

Research evidence / Overview of studies for Clofoctol

The clinical evaluation of Clofoctol relies on a historical body of research, primarily consisting of clinical studies and trials conducted in the 1980s, which served as the initial evidence foundation. The research examined changes observed over defined time intervals, rather than through large-scale, recent comparative trials.

---

Evidence for Use in Ear, Nose, and Throat (ENT) Infections

The research examined the use of Clofoctol in conditions involving the upper respiratory tract, such as tonsillitis and infections of the middle ear. These older clinical studies were used in research exploring how symptoms evolve in the observed populations, particularly in populations that included children.

In these trials, researchers monitored outcomes related to physical discomfort and tracked bacteriological outcomes to observe patterns related to the clearance or persistence of susceptible Gram-positive pathogens. Research describes patterns related to the use of Clofoctol in managing diseases common to ENT practice. The evidence is characterized by its age, with a reliance on data from the 1980s. Long-term effects are not fully established, and there is a paucity of recent, large-scale, high-quality Randomized Controlled Trials (RCTs) to confirm findings using contemporary standards.

---

Evidence for Use in Lower Respiratory Tract Infections

Clofoctol was evaluated in older clinical studies focusing on adult hospitalized patients diagnosed with infectious bronchopulmonary diseases, including acute bronchitis and pneumonia. In this research, studies monitored outcomes related to systemic or functional imbalance, such as body temperature and cough. Furthermore, studies monitored specific objective measures related to lung function, such as Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1), with research describing measured shifts during the study period. Findings describe patterns observed in the studies related to bacteriological clearance, and overall patient status was often assessed using composite scores at the conclusion of the study.

The Strength of Evidence and Research Gaps

The certainty of the evidence remains low when measured against contemporary standards that prioritize large, recent Randomized Controlled Trials (RCTs). The main supporting research consists of older clinical trials, which means comparative evidence is lacking against currently used standard treatments. The findings describe group patterns observed in the studies, but the research does not determine whether an individual will respond similarly. This evidence highlights what is known—and what is still uncertain—about this medicine.

Key Studies & References

1. J01XX03 - Other antibacterials: Clofoctol (WHO ATC Classification)

Common questions about Clofoctol (FAQ)

Q: Is Clofoctol intended to treat all types of bacterial infections?

A: Official product information on Clofoctol's activity specifies its use for infections caused by certain Gram-positive bacteria. This indicates its therapeutic scope is focused on a specific group of pathogens and is not generally intended for all types of bacterial infections, such as those caused by Gram-negative bacteria.

---

Q: Are there different instructions for using Clofoctol suppositories in children versus adults?

A: Yes, regulatory documents recognize different dosing requirements for children compared to adults. Lower dosage strengths, such as 100 mg and 200 mg, are available for the pediatric population. The specific administration details are outlined in regulatory documents based on the child's age or weight.

---

Q: What are the most commonly reported side effects of Clofoctol?

A: The official safety profile organizes and lists potential adverse reactions by frequency and body system. This classification provides information on which side effects are classified as common or very common.

---

Q: Is it normal to experience mild gastrointestinal upset, like nausea or diarrhea, with Clofoctol?

A: Gastrointestinal disturbances, such as nausea or diarrhea, are listed among the possible adverse effects in the official safety information. The frequency classification in regulatory documents indicates how often these types of events have been reported in clinical contexts.

---

Q: Are there any signs of an allergic reaction to Clofoctol that require immediate attention?

A: The official regulatory label establishes a formal contraindication for individuals with known hypersensitivity to the product. The Warnings and Precautions section alerts to the potential for severe allergic reactions and lists associated signs.

---

Q: Does Clofoctol frequently cause side effects such as headache or dizziness?

A: Official safety documents list possible adverse reactions affecting the Nervous System. These documents classify the frequency of side effects like headache and dizziness according to reported clinical data.

---

Q: Can Clofoctol use potentially affect a patient's liver enzyme levels?

A: The official safety profile lists the potential for abnormal liver function test results as a reported event. Furthermore, the drug's use is formally restricted for patients with severe hepatic impairment because the liver is involved in processing the medicine.

---

Q: What should patients taking multiple medications know about Clofoctol?

A: The official prescribing information is notable for the absence of explicit pharmacokinetic or pharmacodynamic interactions that require formal restrictions. Official prescribing information does not currently specify mandatory warnings or timing rules for co-administering Clofoctol with other medicinal products.

---

Q: Does Clofoctol treat viral infections as well as bacterial infections?

A: Clofoctol is officially classified and indicated exclusively as an antibacterial agent. Its therapeutic purpose, as outlined in regulatory documents, is the management of susceptible bacterial infections, not infections caused by viruses.

---

Q: Is Clofoctol the brand name or is the brand name Octofene?

A: Clofoctol is the International Nonproprietary Name (INN) for the active substance itself. The name Octofene is recognized as one of the brand names under which the final finished product has been, or is currently, commercially marketed in certain regions.

---

Q: Is Clofoctol a broad-spectrum or narrow-spectrum antibacterial agent?

A: Official documents indicate that the drug's activity is primarily directed against certain Gram-positive bacteria. This specific targeting of a limited group of bacteria is characteristic of a narrow-spectrum profile.

---

Q: What should I expect for the time it takes for Clofoctol to start working?

A: The specific time frame until the medicine begins to show a noticeable clinical effect is addressed in the Pharmacodynamic section of the official regulatory documentation. This section summarizes data collected on the drug’s biological activity.

---

Q: How long does the active substance of Clofoctol stay in the body after the last dose?

A: Pharmacokinetic data, found in the official label, details how the drug moves through the body, including its elimination rate. This data provides the elimination half-life (T1/2), which describes the time required for the amount of drug in the body to be reduced by half.

---

Q: Is there a liquid or tablet form of Clofoctol available?

A: Official regulatory documents list the currently approved pharmaceutical form as a suppository for rectal administration. Regulatory documents currently do not list authorized tablet or liquid formulations for patient use.

---

Q: What happens if a scheduled dose of Clofoctol is missed?

A: Official dosing instructions provide guidance on the steps generally advised when a scheduled dose of the medicine has been missed.

---

Q: Can patients crush or split a Clofoctol tablet if one is prescribed?

A: The official authorized form is a suppository. Regulatory administration instructions are provided only for this specific form and do not include guidance for crushing or splitting any component.

---

Q: How does the rectal administration of Clofoctol affect its absorption?

A: Pharmacokinetic data in the official label specifically addresses the drug's absorption profile after being administered rectally. This information helps describe how the active substance enters the bloodstream.

---

Q: Is there a risk of serious skin reactions, like Stevens-Johnson syndrome, with Clofoctol?

A: Official warnings and precautions sections address the risk and potential for serious adverse events. This includes information regarding the potential for specified severe dermatologic reactions, such as Stevens-Johnson syndrome.

---

Q: Does Clofoctol carry a risk of antibiotic resistance?

A: Official regulatory warnings typically address the general risk associated with the use of antibacterial agents. These statements caution about the general development of resistance associated with antibacterial agents.

Regulatory documents for the finished medicinal product Clofoctol do not contain specific public-facing instructions for storage temperature or light protection. Therefore, storage must follow general pharmaceutical security and disposal guidelines established by health authorities.

Storage Security and Protection

The medicine must be stored in a secure location that is out of the sight and reach of children, adhering to universal regulatory requirements for all pharmaceutical products.

Disposal of Unused Clofoctol

Official disposal procedures mandate that the product must not be flushed down the toilet or drain. Unused or expired medication should first be offered to a drug take-back program.

If a take-back program is unavailable, the product must be mixed with an undesirable substance (such as dirt or kitty litter), placed in a sealed container, and then discarded in the household trash. All identifying information on the original container must be removed or defaced prior to disposal.